<DOC>
	<DOC>NCT02259647</DOC>
	<brief_summary>60 patients of radiological, biopsy proven advanced HCC (Hepatocellular carcinoma) patient will be randomized into two groups. Cases group will receive Sorafenib plus vitamin K and control group will receive Sorafenib plus placebo</brief_summary>
	<brief_title>Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age 18 to 70 years Child A and B cirrhosis with hepatocellular carcinoma Biochemical, Radiological, histological evidence of advanced hepatocellular carcinoma diagnosed as stage C and stage d with serum bilirubin &lt;5 mg/dl according to BCLC staging system HCC with portal vein thrombosis Unresectable cancer, as assessed carefully by individual experts No recent active treatment like surgery, radiofrequency ablation, trans arterial chemo embolization, radiotherapy, chemotherapy (within the past 6 months) Patients with endstage hepatocellular carcinoma (Stage D, BCLC)with poor performance status Child C cirrhosis with HCC (Hepatocellular carcinoma) HCC with acute decompensated state of CLD GI bleed, increased jaundice, HE, SBP (Spontaneous Bacterial Peritonitis) Acute febrile illness Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>